UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Luxturna to open gene therapies market: analyst
The latest approval by the U.S. Food and Drug Administration for Luxturna, ...
by Nam Doo-hyun
|
2018-01-10 15:48
라인
Test for fetal sex chromosome defects wins patent
A local firm has won a patent in testing fetal sex chromosome abnormalities...
by Nam Doo-hyun
|
2018-01-10 14:39
라인
Antibodies drug suggested against N. Korean anthrax threat
Amid growing concerns over biological terrorism with North Korea’s reported...
by Nam Doo-hyun
|
2018-01-05 12:03
라인
Venture capital investment in biomedical sector drops 20% in 2017
Venture capital investment in the local biomedical sector declined by 20 pe...
by Nam Doo-hyun
|
2018-01-04 09:30
라인
70% of biotech firms enjoy stock price gains in 2017
In the South Korean stock market, biopharmaceutical and pharmaceutical firm...
by Nam Doo-hyun
|
2018-01-02 17:42
라인
Kolon Life Science’s shares plummet on drifting export deal
Kolon Life Science’s shares plummeted by 15 percent on Wednesday from the p...
by Nam Doo-hyun
|
2017-12-21 13:16
라인
₩500-billion Invossa technology export to Japan in peril
Mitsubishi Tanabe Pharma notified Kolon Life Science that the Japanese drug...
by Nam Doo-hyun
|
2017-12-20 14:59
라인
Will Takeda, Dong-A ST benefit from new hypertension guideline?
As Takeda Pharmaceuticals Korea is about to release its angiotensin recepto...
by Nam Doo-hyun
|
2017-12-19 16:15
라인
Boehringer Ingelheim Korea’s labor union protests early retirement program
The labor union of Boehringer Ingelheim Korea said the company’s recent ann...
by Nam Doo-hyun
|
2017-12-19 14:35
라인
‘Celltrion’s annual revenue to top ₩3 trillion in 5 years’
Celltrion, which recently obtained Europe’s approval for breast cancer trea...
by Nam Doo-hyun
|
2017-12-18 15:55
라인
Yuhan’s chemo combo YH24931 more effective than immunotherapy alone
Yuhan Corp.’s combination of chemotherapy with immunotherapy YH24931 has st...
by Nam Doo-hyun
|
2017-12-18 11:51
라인
‘Postmenopausal women in 50s shouldn’t take phytoestrogen’
Over-the-counter drugs and health functional foods to alleviate symptoms of...
by Nam Doo-hyun
|
2017-12-18 10:49
라인
‘Surge of gene-therapy providing hospitals to benefit Invossa’
With hospitals increasingly registering as a provider of gene therapies, Ko...
by Nam Doo-hyun
|
2017-12-12 15:59
라인
PCL shares rise despite regulator’s warning
Shares of PCL, a provider of in vitro diagnostic products, have risen again...
by Nam Doo-hyun
|
2017-12-12 11:02
라인
Oscotec shares rebound on launch of US clinical trial
Shares of Oscotec rebounded on Monday on the company’s announcement that it...
by Nam Doo-hyun
|
2017-12-11 15:50
라인
ToolGen’s shares jump on gene therapy market expectations
With rising expectations for a rapid growth of gene therapy market, investo...
by Nam Doo-hyun
|
2017-12-11 15:16
라인
Government’s mobile healthcare pilot project proves effective
The Ministry of Health and Welfare said its pilot mobile healthcare program...
by Nam Doo-hyun
|
2017-12-07 14:37
라인
Novartis Korea faces tax investigation
The National Tax Service launched a tax investigation into Novartis Korea o...
by Nam Doo-hyun
|
2017-12-06 10:55
라인
Kolon Life Science confident to make Invossa global blockbuster
Despite proved efficacy in reducing pain for osteoarthritis patients, Kolon...
by Nam Doo-hyun
|
2017-12-06 09:30
라인
Shares of biotech firms, listed with ‘exceptional techs,’ rise above offer price
Most of the biotechnology companies, listed on Kosdaq early this year under...
by Nam Doo-hyun
|
2017-12-05 14:38
-
1
2
3
4
5
6
7
8
9
10
다음
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top